Needle bleb revision of encapsulated filtering bleb with bevacizumab.
The utility of needle bleb revision with bevacizumab in a patient with a failing bleb following trabeculectomy is explored. The patient had previously failed needle bleb revision with mitomycin C. After needling and injection of 1 mg of bevacizumab, the bleb was noted to be more diffuse with a decrease in surface neovascularization. Bevacizumab may be an effective medication for rescuing failing filtering blebs that exhibit neovascularization.
Kahook
Malik Y
MY
UPMC Eye Center, Eye and Ear Institute, Pittsburgh, Pennsylvania 15213, USA.
Schuman
Joel S
JS
Noecker
Robert J
RJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001768:Blister / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D003228:Conjunctiva / Q000098:blood supply / Q000187:drug effects; D005500:Follow-Up Studies; D005901:Glaucoma / Q000601:surgery; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000517:prevention & control; D009798:Ocular Hypertension / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012086:Reoperation; D014130:Trabeculectomy; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab